Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

TAM receptors in leukemia: expression, signaling, and therapeutic implications.

Brandão L, Migdall-Wilson J, Eisenman K, Graham DK.

Crit Rev Oncog. 2011;16(1-2):47-63.

2.

Targeting the TAM Receptors in Leukemia.

Huey MG, Minson KA, Earp HS, DeRyckere D, Graham DK.

Cancers (Basel). 2016 Nov 8;8(11). pii: E101. Review.

3.

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Linger RM, Keating AK, Earp HS, Graham DK.

Adv Cancer Res. 2008;100:35-83. doi: 10.1016/S0065-230X(08)00002-X. Review.

4.

Axl as a mediator of cellular growth and survival.

Axelrod H, Pienta KJ.

Oncotarget. 2014 Oct 15;5(19):8818-52. Review.

5.

Targeting Axl and Mer kinases in cancer.

Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S.

Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Review.

6.

The roles of TAM receptor tyrosine kinases in the mammalian testis and immunoprivileged sites.

Deng T, Chen Q, Han D.

Front Biosci (Landmark Ed). 2016 Jan 1;21:316-27. Review.

PMID:
26709775
7.

Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

Rothlin CV, Leighton JA, Ghosh S.

Inflamm Bowel Dis. 2014 Aug;20(8):1472-80. doi: 10.1097/MIB.0000000000000050. Review.

8.

TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system.

Pierce AM, Keating AK.

Brain Res. 2014 Jan 13;1542:206-20. doi: 10.1016/j.brainres.2013.10.049. Review.

9.

TAM receptor signaling in immune homeostasis.

Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S.

Annu Rev Immunol. 2015;33:355-91. doi: 10.1146/annurev-immunol-032414-112103. Review.

10.

TAM receptor signalling and demyelination.

Binder MD, Kilpatrick TJ.

Neurosignals. 2009;17(4):277-87. doi: 10.1159/000231894. Review.

PMID:
19816064
11.

Molecular pathways: MERTK signaling in cancer.

Cummings CT, Deryckere D, Earp HS, Graham DK.

Clin Cancer Res. 2013 Oct 1;19(19):5275-80. doi: 10.1158/1078-0432.CCR-12-1451. Review.

12.

Axl-dependent signalling: a clinical update.

Korshunov VA.

Clin Sci (Lond). 2012 Apr;122(8):361-8. doi: 10.1042/CS20110411. Review.

13.

The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy.

Paolino M, Penninger JM.

Cancers (Basel). 2016 Oct 21;8(10). pii: E97. Review.

14.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Linger RM, Keating AK, Earp HS, Graham DK.

Expert Opin Ther Targets. 2010 Oct;14(10):1073-90. doi: 10.1517/14728222.2010.515980. Review.

15.

Biology of the TAM receptors.

Lemke G.

Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a009076. doi: 10.1101/cshperspect.a009076. Review.

16.

Immunobiology of the TAM receptors.

Lemke G, Rothlin CV.

Nat Rev Immunol. 2008 May;8(5):327-36. doi: 10.1038/nri2303. Review.

17.

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H.

Curr Pharm Des. 2004;10(16):1867-83. Review.

PMID:
15180525
18.

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.

Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P.

Curr Med Chem. 2016;23(15):1496-512. Review.

PMID:
27048336
19.

Axl kinase as a key target for oncology: focus on small molecule inhibitors.

Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Daydé-Cazals B, Warnault P, Chevé G, Yasri A.

Mol Cancer Ther. 2014 Sep;13(9):2141-8. doi: 10.1158/1535-7163.MCT-13-1083. Review. Erratum in: Mol Cancer Ther. 2015 Jun;14(6):1518.

20.

TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis.

van der Meer JH, van der Poll T, van 't Veer C.

Blood. 2014 Apr 17;123(16):2460-9. doi: 10.1182/blood-2013-09-528752. Review.

Supplemental Content

Support Center